Nanosphere Health Sciences (FRA:2CG) Total Liabilities: €1.17 Mil (As of Dec. 2025)


What is Nanosphere Health Sciences Total Liabilities?

Nanosphere Health Sciences FRA:2CG Total Liabilities is €1.17 Mil as of Dec. 2025.

Nanosphere Health Sciences's Total Liabilities for the quarter that ended in Dec. 2025 was €1.17 Mil.

Nanosphere Health Sciences's quarterly Total Liabilities declined from Jun. 2025 (€1.21 Mil) to Sep. 2025 (€1.18 Mil) and declined from Sep. 2025 (€1.18 Mil) to Dec. 2025 (€1.17 Mil).

Nanosphere Health Sciences's annual Total Liabilities declined from Dec. 2023 (€1.44 Mil) to Dec. 2024 (€1.18 Mil) and declined from Dec. 2024 (€1.18 Mil) to Dec. 2025 (€1.17 Mil).

Nanosphere Health Sciences Total Liabilities Historical Data

* Premium members only.

The historical data trend for Nanosphere Health Sciences's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanosphere Health Sciences Total Liabilities Chart

Nanosphere Health Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.07 1.30 1.44 1.18 1.17

Nanosphere Health Sciences Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.18 1.23 1.21 1.18 1.17

Nanosphere Health Sciences Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Nanosphere Health Sciences's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.168+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.17

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=0.015--1.154
=1.17

Nanosphere Health Sciences's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.168+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.17

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=0.015--1.154
=1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €1.17 Mil mean?
Nanosphere Health Sciences (FRA:2CG) has a Total Liabilities of €1.17 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nanosphere Health Sciences and its competitors.
Is Nanosphere Health Sciences' Total Liabilities too high?
Nanosphere Health Sciences' current Total Liabilities is €1.17 Mil.
How does Nanosphere Health Sciences' Total Liabilities compare to VRTX and REGN?
Nanosphere Health Sciences' Total Liabilities of €1.17 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Nanosphere Health Sciences and its competitors. Nanosphere Health Sciences's current Total Liabilities is €1.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanosphere Health Sciences stock overvalued right now?
Nanosphere Health Sciences (FRA:2CG) has a current Total Liabilities of €1.17 Mil. The current Total Liabilities is €1.17 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Nanosphere Health Sciences (FRA:2CG), the current Total Liabilities is €1.17 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanosphere Health Sciences Business Description

Other Exchanges NSHSF:USANSHS:Canada
Address 605 Robson Street, c/o Suite 430, Vancouver, BC, CAN, V6B 5J3
Nanosphere Health Sciences Inc is a biotechnology company focused on providing next generation delivery of biologically active compounds through licensing and joint venture arrangements. The Company has developed and is commercializing its patented NanoSphere Delivery System, a nanotechnology platform for the delivery of biological agents such as cannabinoids, supplements, nutraceuticals, and over-the-counter medications for the cannabis, pharmaceutical, and animal health industries. The NanoSphere Delivery System provides improved bioavailability, efficacy, and onset of effect over traditional delivery systems.